![]() ![]() Inadequate clinical evaluation" Prescrire International 2020 29 (217): 173-176. Source: "Andexanet alfa (Ondexxya°) as an antidote to xabans. ![]() When bleeding occurs in a patient receiving a xaban, the key action is to put in place proven emergency supportive measures. Further evaluation is needed, with the aim of providing comparative data based on clinical criteria. NOTHING NEW As of 2020, the efficacy of andexanet alfa has not been demonstrated using clinical endpoints.Andexanet alfa carries a risk of infusion reactions. ![]() It is not known whether these events were linked to withdrawal of the anticoagulant in patients at risk of thrombosis, or to a procoagulant effect of andexanet alfa.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |